Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 131Liver Neoplasms 42Carcinoma, Renal Cell 36Leukemia, Myeloid, Acute 32Neoplasm Metastasis 26Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Kidney Neoplasms 16Neoplasms 14Prostatic Neoplasms 12Pancreatic Neoplasms 12Recurrence 11Lung Neoplasms 11Colorectal Neoplasms 10Sarcoma 9Melanoma 9Brain Neoplasms 9Myelodysplastic Syndromes 8Glioblastoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Thyroid Neoplasms 5Rectal Neoplasms 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Stomach Neoplasms 4Ovarian Neoplasms 4Liver Diseases 4Gliosarcoma 4

Interventions

surufatinib 1pembrolizumab 1lenvatinib 1apatinib 1Sorafenib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Differentiated Thyroid Cancer × Sorafenib × Clear all
NCT01263951 2021-10-26

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

Thomas Jefferson University

Phase 2 Unknown
35 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡